For cell and gene therapy teams, the new CMC playbook means you need to prove product control earlier, not assemble Chemistry, Manufacturing, and Controls documents later. Regulators now expect potency, comparability, materials, analytics, and lifecycle change plans to mature alongside the clinical program.
That shift changes how you plan budgets, assign ownership, engage regulators, and decide when a process is ready to move forward. If your team treats CMC as a late-stage submission package, you risk avoidable questions, rework, and delays at the exact point when speed matters most. This article explains what the CMC playbook means in practical terms and how to build a cell and gene therapy program that can stand up to technical and regulatory review.
Why CMC Has Become The Bottleneck In Cell And Gene Therapy Approvals
Chemistry, Manufacturing, and Controls (CMC) has become a bottleneck because cell and gene therapies are difficult to define, difficult to measure, and difficult to reproduce at scale. You’re often working with living cells, viral vectors, patient-specific starting material, or biologically complex intermediates. Small process changes can affect identity, potency, purity, safety, and consistency. Regulators are asking whether you understand those risks before the program reaches a late clinical stage.
Clinical promise alone doesn’t solve a weak control strategy. A therapy can show encouraging patient data and still face major CMC questions if the manufacturing process, assays, raw materials, or release criteria are underdeveloped. This is especially true when early clinical batches were made with one process and pivotal or commercial batches rely on a changed process. The burden is on your team to connect the product you tested clinically with the product you plan to keep making.
The pressure is greater for small biotechnology teams because CMC work competes with clinical execution, fundraising, manufacturing slots, and talent shortages. You may not have a full internal analytics group, process development group, quality team, regulatory Chemistry, Manufacturing, and Controls lead, and supply chain function. That makes prioritization matter. The new expectation is not perfection on day one; it’s disciplined, phase-appropriate evidence that you know the product, know the risks, and are reducing uncertainty over time.
What The New CMC Playbook Actually Refers To
The “new CMC playbook” is not the title of one official agency document. It’s an industry shorthand for a group of regulatory expectations around gene therapy Investigational New Drug applications, potency assurance, manufacturing changes, comparability, viral safety, analytical procedure development, and lifecycle management. You should treat it as a shift in operating model. The center of gravity has moved from document assembly to product control.
For gene therapy Investigational New Drug (IND) submissions, the United States Food and Drug Administration (FDA) describes the CMC information sponsors should provide, including manufacturing, characterization, quality testing, and control of the investigational product. The agency’s cellular and gene therapy guidance pages also point teams toward related guidance that affects how you design development plans. International Council for Harmonisation (ICH) quality guidance adds another layer, especially for viral safety, analytical procedure development, and post-approval change management. European Medicines Agency (EMA) guidance for advanced therapy medicinal products (ATMPs) matters when your program has global goals.
Practically, the CMC playbook asks your team to answer five linked questions. What are you making, and which attributes matter most? How do you know the product is potent, pure, safe, and consistent? What process parameters and materials affect those attributes? What evidence supports changes in the process or manufacturing site? How will the control strategy mature from early clinical batches to commercial supply?
The Shift From CMC Checklist To Risk-Based Control Strategy
A checklist mindset asks whether the submission contains the expected sections. A risk-based control strategy asks whether your data, process knowledge, and specifications support safe and consistent manufacturing. That distinction matters because cell and gene therapies often have limited batch history, short timelines, scarce material, and complex biology. You need a plan that explains which risks matter most and how your team manages them.
Start with a quality target product profile. That means defining the intended product characteristics, route of administration, patient population, dose form, key quality attributes, storage needs, and performance expectations. From there, connect quality attributes to process steps, analytical methods, raw materials, and release tests. This gives your CMC team a technical map instead of a loose collection of documents.
A strong risk-based strategy also helps you avoid overbuilding early and underbuilding late. Early development can be phase-appropriate, but it can’t be careless. You don’t need every commercial method finalized before first-in-human work, but you do need a credible path showing how methods, specifications, comparability tools, and process controls will mature. That path becomes especially valuable when you discuss CMC plans with regulators before pivotal studies.
Potency Assurance: The Core Change CMC Teams Must Understand
Potency assurance means your team needs more than one late-stage potency assay. You need a strategy that links product biology, mechanism of action, analytical methods, process controls, and acceptance criteria. For many cell and gene therapies, one test cannot capture all relevant functions. Regulators now expect sponsors to think about potency as a development program, not a box checked near licensure.
This is hard when product material is limited. Autologous cell therapies may have variable starting material from patient to patient. Gene therapies may require assays that connect vector properties, expression, activity, and biological function. Your team may need a matrix of assays, including identity, viability, purity, transduction or transfection-related measures, functional readouts, and surrogate activity measures. The logic connecting those assays to clinical performance matters as much as the individual method.
Build potency work early by documenting the product’s proposed mechanism of action and ranking which biological activities are most tied to intended effect. Then compare candidate assays based on relevance, precision, sensitivity, material needs, turnaround time, transferability, and ability to support release. Some assays may begin as characterization tools before they become release or stability methods. That progression is acceptable when you can explain the rationale and show steady method development.
Comparability And Manufacturing Changes: Planning From Day One
Comparability planning protects your program when the process changes. Cell and gene therapy teams often change manufacturing scale, vector source, plasmid supplier, cell culture conditions, media, equipment, facility, cryopreservation process, or analytical methods during development. Those changes may be necessary, but each one can raise a regulatory question. You need evidence that pre-change and post-change products remain comparable for their intended use.
The mistake is waiting until a change is urgent before designing the comparability package. A better plan identifies likely changes early and defines the data needed before and after each change. That may include side-by-side analytical testing, extended characterization, stability data, process performance data, impurity profiles, and, when needed, nonclinical or clinical bridging considerations. The higher the risk and the closer you are to pivotal or commercial manufacturing, the stronger the evidence should be.
Your comparability plan should also control version history. Keep a clear record of process changes, materials changes, method changes, site changes, and acceptance criteria changes. Tie each change to risk assessment, testing rationale, results, and regulatory communication decisions. This discipline prevents your CMC story from becoming fragmented when reviewers ask how the product made for early studies relates to the product intended for broader use.
Vector And Starting Material Characterization: Expectations Are Rising
Vector and starting material characterization sits near the center of the new CMC playbook because these inputs shape product quality before manufacturing begins. For gene therapy, vector design, vector production, plasmids, cell banks, helper components, impurities, replication-competent virus testing, and viral safety controls all influence the product risk profile. For cell therapy, donor material, cell source, collection methods, enrichment steps, activation, genetic modification, expansion, and cryopreservation can affect consistency.
Your team should treat starting materials and raw materials as controlled inputs, not background details. Define supplier qualifications, certificates of analysis, testing requirements, change notification terms, and backup supply plans. If a supplier changes a material, your manufacturing process may change with it. That can create comparability work you didn’t budget for.
Viral safety and impurity control need early attention as well. International guidance on viral safety now addresses newer biotechnology and gene therapy modalities, including viral vectors. Analytical development guidance also pushes teams to think about method purpose, performance, lifecycle use, and control strategy fit. The message is practical: if a material or vector-related attribute can affect safety, potency, or consistency, you need a plan to measure and control it.
How CMC Teams Should Reorganize: Skills, Systems, And Timelines
The CMC playbook changes team design. You need cross-functional ownership across process development, analytical development, quality, manufacturing, supply chain, regulatory affairs, and clinical operations. If these groups work in separate lanes, CMC decisions arrive late and create rework. If they plan together, you can align manufacturing changes, assay readiness, clinical milestones, and regulatory meetings.
Small teams should assign named owners for potency, comparability, materials, specifications, stability, vendor oversight, and regulatory CMC communication. These roles don’t always require large departments, but they do require accountability. Contract manufacturing organizations and testing laboratories can provide execution capacity, but your sponsor team still owns the development logic. Regulators will expect you to understand and defend the work done on your behalf.
Systems matter as much as skills. Use controlled document practices for process descriptions, batch records, analytical methods, deviations, change controls, and reference standards. Create a living CMC risk register that tracks open technical risks, planned studies, decision points, and regulatory questions. This helps you use limited time and budget on the work that reduces program risk instead of spreading effort thinly across low-value tasks.
Early FDA Engagement: INTERACT, Pre-IND, And CMC-Focused Meetings
Early regulatory engagement helps you test your CMC assumptions before they become expensive commitments. INTERACT meetings, pre-Investigational New Drug meetings, and other CMC-focused interactions can be useful when your questions are specific, data-supported, and tied to near-term decisions. Don’t use meetings as general education sessions. Use them to confirm whether your planned evidence is fit for the development stage.
Before you request a meeting, sharpen the question. Ask whether your potency strategy is reasonable for the planned study, whether a manufacturing change package is adequate, whether a proposed release panel fits the product risk, or whether your viral safety plan addresses the relevant concerns. Provide enough background for reviewers to understand your product and decision point. Vague questions tend to produce limited answers.
Good meeting preparation includes briefing materials that connect product design, manufacturing process, analytics, risks, and proposed controls. Your goal is not to obtain broad approval of every CMC choice. Your goal is to reduce avoidable misalignment before first-in-human dosing, before a major process change, before pivotal studies, or before Biologics License Application (BLA) preparation. The earlier you identify disagreement, the cheaper it is to respond.
CMC Readiness For BLA: Building A Commercial Control Strategy
Biologics License Application readiness requires more than successful clinical manufacturing. By the time you approach a BLA, your team needs a commercial control strategy that covers process validation, analytical validation, specifications, stability, facility readiness, supply chain controls, comparability history, and lifecycle change management. The product made commercially must be tied back to the product that supported clinical benefit. That connection needs data, not assumptions.
Commercial readiness also requires mature analytical methods. Potency, identity, purity, impurity, safety, and quantity methods should have defined purposes and performance expectations. Methods used for release and stability need stronger validation than early characterization tools. If you delay analytical maturation, you may discover too late that an assay is too variable, too slow, too material-intensive, or too hard to transfer.
Post-approval change planning belongs in the same conversation. Cell and gene therapy manufacturing rarely stays static after launch. You may need site additions, scale changes, raw material changes, equipment changes, or method updates. International guidance on lifecycle management can help structure how you plan and communicate those changes, but your internal change control discipline must be ready before approval.
Action Plan: A Phased Roadmap For Cell And Gene Therapy CMC Teams
In early development, focus on product definition, risk ranking, starting material controls, initial process understanding, candidate potency assays, and a practical release panel. Don’t overpromise what the process can support. Document what is known, what remains uncertain, and which studies will close the gap. That transparency gives your team a stronger basis for regulatory discussion.
Before pivotal development, tighten comparability plans, analytical method readiness, specifications, stability strategy, manufacturing scale, vendor controls, and quality systems. This is the stage where weak CMC planning becomes visible. If you plan a major manufacturing change, define the bridging package before locking the clinical timeline. If potency remains unresolved, treat it as a program risk that needs executive attention, not a technical side project.
Before BLA submission, pressure-test the full CMC story. Review whether the commercial process is adequately defined, whether critical attributes are controlled, whether assays are validated for their intended use, whether process changes are justified, and whether manufacturing sites are inspection-ready. The strongest teams build this readiness gradually. The weakest teams discover late that their CMC evidence doesn’t match the ambition of their clinical program.
What The New CMC Playbook Means
- Invest earlier in CMC
- Plan potency from day one
- Control materials and vectors
- Prepare comparability early
- Use FDA meetings before pivotal work
Build The CMC Playbook Before The Program Needs Rescue
The new CMC playbook rewards teams that build product understanding early and keep it connected to clinical, manufacturing, and regulatory decisions. You don’t need every answer at the start, but you do need a disciplined way to reduce uncertainty as the product advances. Potency, comparability, vector and starting material control, analytical maturity, and lifecycle planning should move in step with the clinical plan. If your team waits until late development to organize the CMC story, you may spend more time explaining gaps than advancing the product. Build the control strategy now, and your future regulatory conversations become much easier to manage.
References
- FDA Cellular And Gene Therapy Guidances
- FDA Chemistry, Manufacturing, And Controls Guidances For Biologics
- FDA Gene Therapy Information
- FDA Approved Cellular And Gene Therapy Products
- FDA Potency Assurance For Cellular And Gene Therapy Products Draft Guidance
- International Council For Harmonisation Quality Guidelines
- European Medicines Agency Advanced Therapy Medicinal Product Scientific Guidelines
- Alliance For Regenerative Medicine Sector Reports.
Nirdosh Jagota is the Consultant & Managing Partner, GRQ Biotech Advisors. Nirdosh Jagota has over 30 years of experience in biotech and pharmaceutical industries, leading innovation in regulatory affairs and quality management.
Dr. Nirdosh Jagota has led global teams across US, Europe, Asia Pacific, Latin America, China, India, and Japan. His expertise has been instrumental in the successful submission, approval, and lifecycle management of biologics, small molecules, and vaccines.